Merck & Co Inc
6MK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
75,000
Stocks News & Analysis
stocks
ASX energy giant undervalued despite commissioning challenges
Near-term hurdles, long-term upside.
stocks
Undervalued ASX share upgrades guidance
Market share gains drive earnings upgrade despite a weak US housing backdrop.
stocks
ASX major bank drives strong quarterly profit
Profit momentum remains robust yet shares overvalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,047.10 | 14.80 | 0.16% |
| CAC 40 | 8,406.06 | 33.78 | 0.40% |
| DAX 40 | 25,361.03 | 262.03 | 1.04% |
| Dow JONES (US) | 52,210.08 | 262.83 | 0.51% |
| FTSE 100 | 10,781.75 | 45.52 | 0.42% |
| HKSE | 25,227.29 | 20.11 | 0.08% |
| NASDAQ | 24,932.08 | 43.74 | -0.18% |
| Nikkei 225 | 62,046.46 | 2,884.73 | -4.44% |
| NZX 50 Index | 13,864.45 | 13.76 | 0.10% |
| S&P 500 | 7,413.18 | 1.20 | 0.02% |
| S&P/ASX 200 | 8,883.60 | 21.40 | 0.24% |
| SSE Composite Index | 3,818.35 | 39.89 | -1.03% |